Phase 1 Study of Apatinib as an Inhibitor of Angiogenesis
Apatinib is a tyrosin-inhibitor agent targeting at VEGFR (vasoendothelial growth factor
receptor) to inhibit tumor angiogenesis. The anti-angiogenesis effect of apatinib has been
viewed in preclinical tests (see protocol). This phase I clinical study is going to evaluate
its toxicity and to find an appropriate dose level to be used in a phase II study in heavily
treated solid tumor patients.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
toxicity and tolerable dosage on the basis of NCI-CTCAE 3.0
4 weeks
Yes
Jin Li, PhD
Principal Investigator
Fudan University
China: Ethics Committee
2007APA
NCT00633490
July 2007
June 2008
Name | Location |
---|